1518 related articles for article (PubMed ID: 18571892)
21. Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
Cancer Invest; 2008 May; 26(4):344-51. PubMed ID: 18443954
[TBL] [Abstract][Full Text] [Related]
22. [Establishment of 5 resistant ovarian cancer cell strains and expression of resistance-related genes].
Luan YZ; Li L; Li DR; Zhang W; Tang BJ
Zhonghua Fu Chan Ke Za Zhi; 2004 Jun; 39(6):403-7. PubMed ID: 15312326
[TBL] [Abstract][Full Text] [Related]
23. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor.
Zhang Y; Wang J; Xiang D; Wang D; Xin X
Int J Oncol; 2009 Nov; 35(5):1069-79. PubMed ID: 19787261
[TBL] [Abstract][Full Text] [Related]
24. Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents.
Hamberger J; Liebeke M; Kaiser M; Bracht K; Olszewski U; Zeillinger R; Hamilton G; Braun D; Bednarski PJ
Anticancer Drugs; 2009 Aug; 20(7):559-72. PubMed ID: 19491657
[TBL] [Abstract][Full Text] [Related]
25. Glutathione peroxidase 3 is a candidate mechanism of anticancer drug resistance of ovarian clear cell adenocarcinoma.
Saga Y; Ohwada M; Suzuki M; Konno R; Kigawa J; Ueno S; Mano H
Oncol Rep; 2008 Dec; 20(6):1299-303. PubMed ID: 19020706
[TBL] [Abstract][Full Text] [Related]
26. Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells.
Ekblad L; Kjellström J; Johnsson A
Anticancer Drugs; 2010 Jun; 21(5):523-31. PubMed ID: 20168208
[TBL] [Abstract][Full Text] [Related]
27. Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer.
Baker AF; Koh MY; Williams RR; James B; Wang H; Tate WR; Gallegos A; Von Hoff DD; Han H; Powis G
Pancreas; 2008 Mar; 36(2):178-86. PubMed ID: 18376310
[TBL] [Abstract][Full Text] [Related]
28. Platinum drug effects on the expression of genes in the polyamine pathway: time-course and concentration-effect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells.
Varma R; Hector S; Greco WR; Clark K; Hawthorn L; Porter C; Pendyala L
Cancer Chemother Pharmacol; 2007 May; 59(6):711-23. PubMed ID: 17021820
[TBL] [Abstract][Full Text] [Related]
29. Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer.
Scurr LL; Guminski AD; Chiew YE; Balleine RL; Sharma R; Lei Y; Pryor K; Wain GV; Brand A; Byth K; Kennedy C; Rizos H; Harnett PR; deFazio A
Clin Cancer Res; 2008 Nov; 14(21):6924-32. PubMed ID: 18980987
[TBL] [Abstract][Full Text] [Related]
30. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
31. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
Stordal BK; Davey MW; Davey RA
Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
[TBL] [Abstract][Full Text] [Related]
32. Glutathione-related enzymes contribute to resistance of tumor cells and low toxicity in normal organs to artesunate.
Efferth T; Volm M
In Vivo; 2005; 19(1):225-32. PubMed ID: 15796179
[TBL] [Abstract][Full Text] [Related]
33. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma.
Kumar A; Soprano DR; Parekh HK
Cancer Res; 2001 Oct; 61(20):7552-5. PubMed ID: 11606393
[TBL] [Abstract][Full Text] [Related]
34. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
[TBL] [Abstract][Full Text] [Related]
35. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
Sharp SY; Rogers PM; Kelland LR
Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
[TBL] [Abstract][Full Text] [Related]
36. Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells.
Seetharam RN; Sood A; Basu-Mallick A; Augenlicht LH; Mariadason JM; Goel S
Anticancer Res; 2010 Jul; 30(7):2531-8. PubMed ID: 20682979
[TBL] [Abstract][Full Text] [Related]
37. Increasing expression of GST-pi MIF, and ID1 genes in chemoresistant prostate cancer cells.
Yu DS; Hsieh DS; Chang SY
Arch Androl; 2006; 52(4):275-81. PubMed ID: 16728343
[TBL] [Abstract][Full Text] [Related]
38. Human renal UOK130 tumor cells: a drug resistant cell line with highly selective over-expression of glutathione S-transferase-pi isozyme.
Wang W; Liu G; Zheng J
Eur J Pharmacol; 2007 Jul; 568(1-3):61-7. PubMed ID: 17509556
[TBL] [Abstract][Full Text] [Related]
39. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
40. [Establishment of a cisplatin-resistant human ovarian cancer cell line and the mechanism of resistance].
Kikuchi Y; Iwano I; Miyauchi M; Kita T; Kizawa I; Oomori K; Kato K
Nihon Sanka Fujinka Gakkai Zasshi; 1988 Mar; 40(3):379-83. PubMed ID: 3361190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]